41122-35-4

Usage

Uses

Used in Pharmaceutical Industry:
TRANS-2-CHLORO-3,4-DIMETHOXY-B-NITROSTY& is used as an intermediate in the synthesis of high affinity D1 dopamine receptor ligands. These ligands are crucial for the development of drugs targeting the D1 receptor, which plays a significant role in various neurological and psychiatric disorders, such as Parkinson's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). TRANS-2-CHLORO-3 4-DIMETHOXY-B-NITROSTY&'s unique structure allows for the creation of ligands with high selectivity and potency, making it a valuable component in the development of novel therapeutic agents for these conditions.

InChI:InChI=1/C10H10ClNO4/c1-15-8-4-3-7(5-6-12(13)14)9(11)10(8)16-2/h3-6H,1-2H3/b6-5+

Upstream product

• 75-52-5 nitromethane 
• 5417-17-4 2-chloro-3,4-dimethoxybenzaldehyde 
• 75-05-8 acetonitrile 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 621-59-0 isovanillin 
• 37687-57-3 2-chloro-3-hydroxy-4-methoxybenzaldehyde 

Downstream Products

• 67287-36-9 2-(2-chloro-3,4-dimethoxyphenyl)ethylamine 
• 46274-24-2 (5-chloro-3,4-dimethoxyphenyl)ethylamine 
• 1429438-68-5 ethyl 2-chloro-3,4-dimethoxyphenylethylcarbamate 
• 1429438-69-6 5-chloro-6,7-dihydroxy-3,4-dihydroisoquinolin-1(2H)-one 
• 1429438-70-9 5-chloro-6,7-bis((4-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-1(2H)-one 
• 1429438-71-0 5-chloro-6,7-bis((4-methoxybenzyl)oxy)-2-(2-(pyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one 
• 102851-73-0 N-propyl-2-chlorodopamine 
• 102851-72-9 N-ethyl-2-chlorodopamine 
• 102851-71-8 N-methyl-2-chlorodopamine 
• 102851-70-7 2-chlorodopamine 
• 99318-58-8 N-(2-chlorohomoveratryl)propanamide 
• 102851-64-9 2-chlorohomoveratrylacetamide 
• 102851-63-8 (2-chlorohomoveratryl)formamide 
• 99318-59-9 N-(n-propyl)-2-(2-chloro-3,4-dimethoxyphenyl)ethylamine 

Relevant academic research and scientific papers

Chemoselective zinc/HCl reduction of halogenated β-nitrostyrenes: Synthesis of halogenated dopamine analogues

A detailed account regarding the synthesis of 2- and 5-halogenated dopamine is given. The key step is a chemoselective reduction of a nitrostyrene by Zn/HCl at 0 °C. These conditions represent a simple, low-cost alternative to reduction by water-sensitive hydride donors and two-step procedures. Under these conditions, aryl fluoride, chloride, and bromide groups are stable. However, iodine undergoes significant reductive dehalogenation.

ANTIBACTERIAL COMPOUNDS

The present Invention relates to cephalosporin antibacterial compounds of Formula (!): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.

Solid oral preparation containing a pyrrolidine derivative with a catechol group

An oral solid preparation comprising an organic acid or its salt and a catechol compound. The catechol compound is, for example, a pyrrolidine derivative having a catechol group of the following general formula (I). It exhibits an improved absorbability in vivo. STR1

Synthesis and Renal Vasodilator Activity of 2-Chlorodopamine and N-Substituted Derivatives

A four-step synthesis of 2-chlorodopamine (2b) is presented as well as methods for the syntheses of the N-methyl, ethyl, and n-propyl analogues (2c-e).Compounds 2b and 2c were essentially equipotent to dopamine for increasing renal blood flow in anesthesized dogs that had been treated with the α-adrenergic antagonist phenoxybenzamine.The increases in renal blood flow were blocked by the DA1 antagonist (R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine.Compounds 2d and 2e were significantly less potent than dopamine in the same model; the increases in renal blood flow were attenuated by propanolol and blocked by a combination of propanolol and (R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine.The significance of an o-chloro substituent on dopamine analogues for the activation of the DA1 receptor is briefly discussed.

6-HALO-3-LOWER ALKYL-7,8-DIHYDROXY-1-PHENYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES

6-Halo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines whose structures have a lower alkyl substituted at the 3 or N-position have potent and often specific anti-Parkinsonism activity by means of their central dopaminergic effect. The lead compound of the series is 6-chloro-3-methyl-1-phenyl-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepin e as the base or its salts such as the hydrochloride, hydrobromide or methane sulfonate.

2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE-7,8-DIONES

Novel benzazepine derivatives having central and peripheral dopaminergic activity useful in treating Parkinson's and cardiovascular diseases. The compounds have additional use as intermediates for the synthesis of other benzazepines with similar useful properties. The 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-dione derivatives are particularly useful.

Substituted 1-alkylthiophenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds

A group of 1-phenyl-1H-3-benzazepines whose structures are characterized by having a functional thio containing group on the 1-phenyl moiety and which have pronounced peripheral and diminished central dopaminergic activity. This activity is manifested in an anti-hypertensive effect in humans. Particular species of this group include 6-chloro-7,8-dihydroxy-1-p-methylthiophenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its derivatives which have dopaminergic activity.